
Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025.
The Massachusetts-based company announced second-quarter sales of $720.28 million, an increase from $691.69 million reported a year ago, surpassing the consensus estimate of $710.71 million.